nabumetone has been researched along with Hematochezia in 16 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 7.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 3.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| " The aim of the present study was to compare nabumetone, a nonacidic drug, with etodolac on rat gastric mucosal damage and prostanoid synthesis, while concurrently measuring prostanoid production during edema formation in a carrageenan model of paw inflammation." | 3.69 | Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac. ( Blower, PR; Durie, M; Gentry, C; Melarange, R; O'Connell, C, 1994) |
| "Repeat oral dosing of nabumetone for 1 month maintains anti-inflammatory efficacy in a carrageenan model of paw oedema yet does not cause gastrointestinal damage." | 3.68 | Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac. ( Blower, PR; Gentry, C; Melarange, R; O'Connell, C, 1991) |
| "Nabumetone is a nonacidic nonsteroidal antiinflammatory drug (NSAID) that is effective and appears to cause minimal NSAID gastropathy." | 2.38 | Upper gastrointestinal safety with nabumetone. ( Roth, SH, 1992) |
| "Nabumetone proved to be an effective anti-inflammatory agent that was devoid of gastrointestinal irritancy." | 1.29 | Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac. ( Blower, PR; Gentry, C; Melarange, R; Spangler, R; Toseland, CD, 1994) |
| "Nabumetone was less potent and less active in inhibiting the production of gastric mucosal 6-keto-PGF1 alpha compared with indomethacin either ex-vivo or in-vitro." | 1.27 | Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function. ( Melarange, R; Rashbrook, LC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, W | 1 |
| Wang, YM | 1 |
| Li, SL | 1 |
| Yan, M | 1 |
| Li, D | 1 |
| Chen, BY | 1 |
| Cheng, NN | 1 |
| Ashworth, NL | 1 |
| Peloso, PM | 1 |
| Muhajarine, N | 1 |
| Stang, M | 1 |
| Hayllar, J | 1 |
| Bjarnason, I | 1 |
| Melarange, R | 4 |
| Gentry, C | 3 |
| Blower, PR | 3 |
| Toseland, CD | 1 |
| Spangler, R | 1 |
| Voss, GD | 1 |
| Schweitzer, P | 1 |
| Durie, M | 1 |
| O'Connell, C | 2 |
| Lanza, FL | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Chan, FK | 1 |
| Sung, JJ | 1 |
| Ching, JY | 1 |
| Wu, JC | 1 |
| Lee, YT | 1 |
| Leung, WK | 1 |
| Hui, Y | 1 |
| Chan, LY | 1 |
| Lai, AC | 1 |
| Chung, SC | 1 |
| Basson, MD | 1 |
| Panzini, L | 1 |
| Palmer, RH | 1 |
| Huskisson, EC | 1 |
| Roth, SH | 1 |
| Rashbrook, LC | 1 |
| Lussier, A | 2 |
| Davis, A | 1 |
| Lussier, Y | 1 |
| Lebel, E | 2 |
3 reviews available for nabumetone and Hematochezia
| Article | Year |
|---|---|
Gastrointestinal toxicity of newer NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Etodolac; Gastrointestinal Hemorrhage; Humans; N | 1993 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Upper gastrointestinal safety with nabumetone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Chromium Radioisotopes; Clinical Trials | 1992 |
4 trials available for nabumetone and Hematochezia
| Article | Year |
|---|---|
Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Drug Therapy, Co | 2001 |
Effect of nabumetone and aspirin on colonic mucosal bleeding time.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Butanones; Co | 2001 |
Comparative gastrointestinal blood loss associated with placebo, aspirin, and nabumetone as assessed by radiochromium (51Cr).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Chromium Radioisotopes; Double-B | 1989 |
Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Chromium Radioisotopes; Double-B | 1987 |
9 other studies available for nabumetone and Hematochezia
| Article | Year |
|---|---|
Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2004 |
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas | 2005 |
NSAIDs, Cox-2 inhibitors, and the gut.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase Inhibitors; Digestive Sy | 1995 |
Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carr | 1994 |
GI bleeding associated with nabumetone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastrointestinal Hemorrhage; Humans; Male; | 1994 |
Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cecum; De | 1994 |
NSAIDs for the new decade--nabumetone?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Gastrointestinal Hemorrha | 1991 |
Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Diclofenac; E | 1991 |
Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bile Acids and Salts | 1987 |